2020 Avon Court, #4
Charlottesville, VA 22902
434-220-0718
info@diffusionpharma.com
 RSS Feed
  • Home
  • About Us
    • Company History
    • Leadership Team
      • Management Team
        • David Kalergis, JD/MBA
        • John L. Gainer, PhD
        • Matthew W. Hantzmon
        • Ben Shealy, MBA/CFA
        • David R. Jones, M.D.
        • Kim Whitten, PharmD, RAC
        • Robert Murray, PhD
        • James Edward John, III
        • Kelly Hoy
        • Jenny Tornqvist, Ph.D.
        • Tracey Linkous Danner, CTM
      • Board of Directors
        • David Kalergis, JD/MBA
        • John L. Gainer, PhD
        • Mark T. Giles, JD
        • Thomas Byrne, JD
        • Robert W. Adams, JD
      • Scientific Advisory Board
        • John L. Gainer, PhD
        • Stuart A. Grossman, MD
        • John A. Jane, Sr., MD, Ph.D., FRCS(C), FACS
        • David R. Jones, M.D.
        • Guy M. Chisolm, Ph.D.
    • Patent Portfolio
    • News
      • Press Releases
      • Subscribe to our news
      • Key Contacts
    • Contact Us
    • Directions
  • Business Development
  • Investors
  • Pipeline
    • Patient Populations
    • Clinical Development of TSC
  • Science
    • Hypoxia and Hypoxic Conditions
    • Published Research
    • Our Scientific Collaborators

Our Scientific Collaborators

We are building on the successful collaborations we have formed with leading academic research organizations such as The Johns Hopkins University, University of Virginia (UVA), and Uniformed Services University of the Health Sciences (UHSU) and government organizations such as the National Cancer Institute’s (NCI) Adult Brain Tumor Consortium (ABTC), and the Office of Naval Research (ONR).

Further, we are actively seeking to develop partnerships with collaborators to explore the many indications that are characterized by hypoxia at the cellular level, especially with those who specialize in the following therapeutic areas:

  • Cardiovascular (acute and chronic)
  • Oncology
  • Respiratory (acute and chronic)
  • Emergency medicine/trauma
  • Other niche indications

To initiate partnering discussions, please contact Mr. Matt Hantzmon, Vice President Business Development.



Home | About Us | Business Development | Investors | Pipeline | Science


BioNetwork East - Investment Challenge Winner

©2010 Diffusion Pharmaceuticals LLC
Terms of Use